Fig. 3

In vivo CEST-MRI during tumor progression. a Exemplary T2-weighted images and pixelwise MTR_asym maps for ∆Glc-, APT- or 2 ppm-weighted CEST contrast of 4T1 tumors on day three, six and nine after tumor implantation. b-d Boxplots showing quantitative MTR_asym for ∆Glc-, APT- and 2 ppm-weighted CEST contrast of whole 4T1 tumors on day three, six and nine after tumor implantation, with the horizontal line indicating mean and boxes representing the 10^th and 90^th percentile. During progression of 4T1 tumors, ∆Glc- and APT-weighted CEST contrast decreased, while 2 ppm-weighted CEST contrast increased from day three to day nine. e Exemplary T2-weighted images and pixelwise MTR_asym maps for ∆Glc-, APT- and 2 ppm-weighted CEST contrast of 67NR tumors on day three, six and nine after tumor implantation. f–h Boxplots showing quantified MTR_asym for ∆Glc-, APT- and 2 ppm-weighted CEST contrast of whole 67NR tumors on day three, six and nine after tumor implantation, with the horizontal line indicating the mean, and boxes representing the 10th and 90th percentile. During progression of 67NR tumors, ∆Glc- and APT-weighted CEST contrast increased, while 2 ppm-weighted CEST contrast decreased from day three to day nine. ^*p < 0.05, ^**p < 0.01, ^***p < 0.001, ^****p < 0.0001